bluebird bio, a clinical-stage biotech focused on treating severe genetic and orphan diseases with gene therapy, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering. The Cambridge, MA-based company, which was founded in 1992 and booked $1 million in collaboration revenue in the first quarter of 2013, plans to list on the NASDAQ under the symbol BLUE. bluebird bio initially filed confidentially on March 21, 2013. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.
